Figure 6.

Evaluation of the therapeutic effect of the anti-inflammatory drug (CDDO-Me) using [¹⁸F]CB251 PET and BLI. (A) Experimental design of treatments and imaging schedules, including simultaneous [¹⁸F]CB251 PET/MRs and BLIs. (B) Representative [¹⁸F]CB251 PET/MR scans and SUVmax ratios were plotted. (C) Representative BLI image and total flux ratio were plotted. Signal ratios from each modality (SUVmax ratio for PET; Total flux ratio for BLI) were calculated from the region of interest (ROI) of right (intracranially injected with saline, LPS, or LPS plus anti-inflammatory agent CDDO-Me) and left striatum (non-injected) in the mouse brain. The values are mean ± SD. (N=8 for saline-treated; N=12 for LPS-treated; N=5 for LPS plus CDDO-Me).